BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

896 related articles for article (PubMed ID: 26409014)

  • 1. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
    Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
    Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.
    Ali M; Akin A; Bahamondes L; Brache V; Habib N; Landoulsi S; Hubacher D;
    Hum Reprod; 2016 Nov; 31(11):2491-2498. PubMed ID: 27671673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement.
    Bahamondes L; Brache V; Ali M; Habib N;
    Contraception; 2018 Sep; 98(3):181-187. PubMed ID: 29777663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
    Modesto W; Bahamondes MV; Bahamondes L
    Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A.
    Rowe P; Farley T; Peregoudov A; Piaggio G; Boccard S; Landoulsi S; Meirik O;
    Contraception; 2016 Jun; 93(6):498-506. PubMed ID: 26916172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter randomized clinical trial of one-rod etonogestrel and two-rod levonorgestrel contraceptive implants with nonrandomized copper-IUD controls: methodology and insertion data.
    Meirik O; Brache V; Orawan K; Habib NA; Schmidt J; Ortayli N; Culwell K; Jackson E; Ali M;
    Contraception; 2013 Jan; 87(1):113-20. PubMed ID: 23063337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in body composition in women using long-acting reversible contraception.
    Silva Dos Santos PN; Madden T; Omvig K; Peipert JF
    Contraception; 2017 Apr; 95(4):382-389. PubMed ID: 28041992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated disability-adjusted life years averted by long-term provision of long acting contraceptive methods in a Brazilian clinic.
    Bahamondes L; Bottura BF; Bahamondes MV; Gonçalves MP; Correia VM; Espejo-Arce X; Sousa MH; Monteiro I; Fernandes A
    Hum Reprod; 2014 Oct; 29(10):2163-70. PubMed ID: 25085802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant.
    Apter D; Briggs P; Tuppurainen M; Grunert J; Lukkari-Lax E; Rybowski S; Gemzell-Danielsson K
    Fertil Steril; 2016 Jul; 106(1):151-157.e5. PubMed ID: 27016644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, open-label, single arm, multicentre study to evaluate efficacy, safety and acceptability of pericoital oral contraception using levonorgestrel 1.5 mg.
    Festin MP; Bahamondes L; Nguyen TM; Habib N; Thamkhantho M; Singh K; Gosavi A; Bartfai G; Bito T; Bahamondes MV; Kapp N
    Hum Reprod; 2016 Mar; 31(3):530-40. PubMed ID: 26830816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety of intrauterine devices among young women: a systematic review.
    Jatlaoui TC; Riley HEM; Curtis KM
    Contraception; 2017 Jan; 95(1):17-39. PubMed ID: 27771475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices.
    Sivin I; Stern J; Diaz J; Diaz MM; Faundes A; el Mahgoub S; Diaz S; Pavez M; Coutinho E; Mattos CE
    Contraception; 1987 Mar; 35(3):245-55. PubMed ID: 3111785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
    Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
    Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight change at 12 months in users of three progestin-only contraceptive methods.
    Vickery Z; Madden T; Zhao Q; Secura GM; Allsworth JE; Peipert JF
    Contraception; 2013 Oct; 88(4):503-8. PubMed ID: 23582238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
    Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
    Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The performance of levonorgestrel rod and Norplant contraceptive implants: a 5 year randomized study.
    Sivin I; Campodonico I; Kiriwat O; Holma P; Diaz S; Wan L; Biswas A; Viegas O; el din Abdalla K; Anant MP; Pavez M; Stern J
    Hum Reprod; 1998 Dec; 13(12):3371-8. PubMed ID: 9886517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial.
    Todd CS; Jones HE; Langwenya N; Hoover DR; Chen PL; Petro G; Myer L
    PLoS Med; 2020 May; 17(5):e1003110. PubMed ID: 32442189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study.
    Luukkainen T; Allonen H; Haukkamaa M; Holma P; Pyörälä T; Terho J; Toivonen J; Batar I; Lampe L; Andersson K
    Contraception; 1987 Aug; 36(2):169-79. PubMed ID: 3123132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices.
    Sivin I; Stern J; Diaz S; Pavéz M; Alvarez F; Brache V; Mishell DR; Lacarra M; McCarthy T; Holma P
    Am J Obstet Gynecol; 1992 Apr; 166(4):1208-13. PubMed ID: 1566771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Female sexual function in women using LARC methods.
    Trigo ACM; Maron CC; Pinheiro MSA; da Silva SBL; Brito MB
    Gynecol Endocrinol; 2022 Jan; 38(1):68-72. PubMed ID: 34672861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.